Jason Bednar
Stock Analyst at Piper Sandler
(2.25)
# 2,807
Out of 5,127 analysts
199
Total ratings
41.89%
Success rate
-3.49%
Average return
Main Sectors:
Stocks Rated by Jason Bednar
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BDX Becton, Dickinson and Company | Reiterates: Neutral | $205 → $170 | $169.84 | +0.09% | 13 | Feb 10, 2026 | |
| NVST Envista Holdings | Reiterates: Neutral | $21 → $25 | $29.83 | -16.19% | 15 | Feb 6, 2026 | |
| ALGN Align Technology | Maintains: Overweight | $200 → $220 | $196.00 | +12.24% | 33 | Feb 5, 2026 | |
| GEHC GE HealthCare Technologies | Maintains: Overweight | $91 → $94 | $80.13 | +17.31% | 2 | Jan 30, 2026 | |
| MDLN Medline | Initiates: Overweight | $50 | $46.98 | +6.43% | 1 | Jan 12, 2026 | |
| SHC Sotera Health Company | Upgrades: Overweight | $17 → $24 | $17.57 | +36.64% | 4 | Jan 9, 2026 | |
| COO The Cooper Companies | Reiterates: Overweight | $83 → $94 | $82.16 | +14.41% | 15 | Dec 5, 2025 | |
| ICUI ICU Medical | Maintains: Overweight | $153 → $172 | $153.68 | +11.92% | 3 | Nov 7, 2025 | |
| SOLV Solventum | Maintains: Overweight | $94 → $98 | $80.21 | +22.18% | 8 | Nov 7, 2025 | |
| MMSI Merit Medical Systems | Reiterates: Overweight | $105 → $109 | $81.90 | +33.09% | 14 | Oct 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $3.5 → $4 | $4.77 | -16.14% | 8 | Aug 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $200 → $210 | $135.25 | +55.27% | 16 | Aug 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $9 → $2.5 | $1.51 | +65.56% | 12 | Jul 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $34 | $10.51 | +223.50% | 11 | Jun 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $20 → $16 | $13.84 | +15.65% | 8 | Apr 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $83 → $77 | $80.27 | -4.07% | 7 | Apr 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $5 → $4.5 | $4.79 | -5.96% | 3 | Mar 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $260 → $265 | $246.54 | +7.49% | 9 | Feb 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $8 → $6 | $3.69 | +62.82% | 5 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $7 | $7.32 | -4.37% | 5 | Aug 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $70 → $20 | $1.14 | +1,654.39% | 3 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $310 → $372 | $499.53 | -25.53% | 4 | Jan 3, 2024 |
Becton, Dickinson and Company
Feb 10, 2026
Reiterates: Neutral
Price Target: $205 → $170
Current: $169.84
Upside: +0.09%
Envista Holdings
Feb 6, 2026
Reiterates: Neutral
Price Target: $21 → $25
Current: $29.83
Upside: -16.19%
Align Technology
Feb 5, 2026
Maintains: Overweight
Price Target: $200 → $220
Current: $196.00
Upside: +12.24%
GE HealthCare Technologies
Jan 30, 2026
Maintains: Overweight
Price Target: $91 → $94
Current: $80.13
Upside: +17.31%
Medline
Jan 12, 2026
Initiates: Overweight
Price Target: $50
Current: $46.98
Upside: +6.43%
Sotera Health Company
Jan 9, 2026
Upgrades: Overweight
Price Target: $17 → $24
Current: $17.57
Upside: +36.64%
The Cooper Companies
Dec 5, 2025
Reiterates: Overweight
Price Target: $83 → $94
Current: $82.16
Upside: +14.41%
ICU Medical
Nov 7, 2025
Maintains: Overweight
Price Target: $153 → $172
Current: $153.68
Upside: +11.92%
Solventum
Nov 7, 2025
Maintains: Overweight
Price Target: $94 → $98
Current: $80.21
Upside: +22.18%
Merit Medical Systems
Oct 31, 2025
Reiterates: Overweight
Price Target: $105 → $109
Current: $81.90
Upside: +33.09%
Aug 7, 2025
Maintains: Neutral
Price Target: $3.5 → $4
Current: $4.77
Upside: -16.14%
Aug 6, 2025
Maintains: Overweight
Price Target: $200 → $210
Current: $135.25
Upside: +55.27%
Jul 31, 2025
Downgrades: Neutral
Price Target: $9 → $2.5
Current: $1.51
Upside: +65.56%
Jun 27, 2025
Reiterates: Overweight
Price Target: $34
Current: $10.51
Upside: +223.50%
Apr 30, 2025
Maintains: Neutral
Price Target: $20 → $16
Current: $13.84
Upside: +15.65%
Apr 30, 2025
Maintains: Overweight
Price Target: $83 → $77
Current: $80.27
Upside: -4.07%
Mar 28, 2025
Maintains: Overweight
Price Target: $5 → $4.5
Current: $4.79
Upside: -5.96%
Feb 3, 2025
Maintains: Overweight
Price Target: $260 → $265
Current: $246.54
Upside: +7.49%
Nov 7, 2024
Maintains: Overweight
Price Target: $8 → $6
Current: $3.69
Upside: +62.82%
Aug 15, 2024
Reiterates: Overweight
Price Target: $7
Current: $7.32
Upside: -4.37%
Aug 7, 2024
Maintains: Overweight
Price Target: $70 → $20
Current: $1.14
Upside: +1,654.39%
Jan 3, 2024
Maintains: Outperform
Price Target: $310 → $372
Current: $499.53
Upside: -25.53%